Insights from Prothena's Q4 2024 call highlight 2025 milestones: pivotal trial results for birtamimab & Alzheimer's programs.

Vyne Therapeutics has dosed the first participant in a randomised Phase Ib clinical trial of VYN202, an oral treatment for moderate-to-severe plaque psoriasis. The double-blind, placebo-controlled ...

Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

The patch-delivered vaccine trial received $28.5m in funding from US authorities as a potential pandemic preparation.

Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...